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Abstract
Through this study we evaluated whether the HIV-1 tropism determined by genotypic analysis correlates with HIV-1 markers, such as
CD4 cell count and plasma HIV-RNA. The analysis was performed on 1221 HIV-1 B-subtype infected patients with an available V3
sequence (all maraviroc naive). Of them, 532 were antiretroviral therapy (ART) naive and 689 ART experienced. Tropism determination
was performed by using the geno2pheno (co-receptor) algorithm set at a false-positive rate (FPR) of 10% and 2%. Potential associations
of FPR with CD4 cell count and viraemia were evaluated. Association of V3 mutations with genotypic-determined tropism was also
evaluated according to different FPR ranges. About 26% of patients (either ART naive or ART experienced) were infected by X4-tropic
viruses (using the classical 10% FPR cut-off). However, a significantly lower proportion of ART-naive patients had FPR £ 2% in compari-
son with ART-experienced patients (4.9% vs. 12.6%, respectively, p <0.001). The risk of advanced HIV-1 infection (with CD4 cell
count £ 200 cells/mm3) was significantly greater in X4-infected patients, either ART-naive (OR (95% CI)), 4.2 (1.8–9.2); p 0.0006) or
ART-experienced (2.3 (1.4–3.6); p 0.0003), with FPR set at 2% (but not at 10%). This finding was confirmed by multivariable logistic
analysis. No relationship was found between viraemia and FPR £2%. Some X4-related mutations were significantly associated with FPR
£2% (ART-naive patients, S11R, Y21V, G24K and G24R, p £0.001; ART-experienced patients, Y7K, S11R, H13Y, p £0.002). In conclu-
sion, these findings show that within the context of genotypically-assessed CXCR4 tropism, FPR £2% defines (far better than 10%-FPR)
a viral population associated with low CD4 rank, with potentially greater cytopathic effect, and with more advanced disease.
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Introduction
Human immunodeficiency virus type 1 (HIV-1) entry into host
cells is a multistep process that requires sequential interactions
of the envelope glycoprotein gp120, first with the CD4 recep-
tor and then with one of the family chemokine receptors,
mainly CCR5 or CXCR4. The V3 loop in HIV-1 gp120 has
been shown to be critical for co-receptor binding [1], and HIV-
1 strains can be phenotypically classified according to virus abil-
ity to use the CCR5 (R5) and/or CXCR4 (X4) co-receptor.
Pure R5-tropic and pure X4-tropic viruses can use only the
CCR5 and CXCR4 co-receptors to enter target cells, respec-
tively, while a dual-tropic virus can use both co-receptors. In a
dual/mixed-tropic viral population, the use of both co-recep-
tors can be due to the presence of dual-tropic species, to a
mixture of pure R5-tropic and X4-tropic species, or both [2].
HIV-1 co-receptor usage is of central pathological and
clinical importance. Indeed, it has been shown that the use
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of the CXCR4 co-receptor is generally seen in more
advanced stages of disease, and has been associated with an
increased severity of HIV disease, higher viral load, and a
decreased CD4 cell count [3–6].
Blocking the interaction between gp120 and the viral co-
receptors on the host cell has been achieved by using small
molecules able to bind CXCR4 or CCR5 co-receptors:
chemokine co-receptors have thus become a new target for
antiretroviral therapy (ART).
AMD3100 (plerixafor) and AMD3465 are CXCR4 core-
ceptor antagonists able to inhibit HIV-1 [7]. Although
CXCR4 antagonists are the first inhibitors discovered, they
are not in clinics for HIV-1 treatment because they showed
poor efficacy and no oral bioavailability [7,8]. In contrast,
maraviroc, the first antagonist of CCR5 co-receptor, has been
approved for treating HIV-1 disease only in patients infected
by CCR5-tropic viruses and is currently used in clinical prac-
tice. On this basis, the determination of HIV-1 tropism is man-
datory before the prescription of this CCR5 antagonist [9–
11]. In previous years, co-receptor usage determination was
assessed using the phenotypic assay Trofile (Monogram Bio-
sciences, South San Francisco, CA, USA) [12]. Today, geno-
typic tropism testing is commonly carried out in clinical
practice by using the genetic information contained in the
sequence of HIV-1 gp120 V3-loop through web-based bioin-
formatic interpretation tools [1,13,14]. Among the available
algorithms used for genotypic tropism determination, geno2-
pheno(co-receptor) (G2P) is currently the most used and
promising tool, due to its good concordance with phenotypic
results [15–17; 18th Conference on Retroviruses and Oppor-
tunistic Infections, abstract 667]. The result of the interpreta-
tion of this system is given as a percentage score, the false-
positive rate (FPR), ranging from 0% to 100%, that positively
predicts the use of the CCR5 co-receptor. Even though Euro-
pean guidelines advise use of the G2P interpretation system
with the FPR set at 10% [11], there is evidence that indicates
that G2P can provide reliable discrimination between R5 and
X4 sequences also when FPR is set between 5% and 10%
[47th Meeting of Infectious Diseases Society of America,
abstract 297; 17th Conference on Retroviruses and Opportu-
nistic Infections, abstract 92]. Furthermore, recent studies
that were carried out by using ultradeep 454-pyrosequencing
(UDPS) revealed new important information about the rele-
vance of very low FPR. First of all, by UDPS the highest preva-
lence of X4 species (range 35–98%) of the entire viral
population was detected in patients with a FPR <2% obtained
by population sequencing [18th Conference on Retroviruses
and Opportunistic Infections, abstract 667]. In addition, by
longitudinal analysis, UDPS showed that only CXCR4-using
HIV populations with an extremely low FPR (<5%) were
selected by maraviroc in patients who started an anti-CCR5
therapy with X4 dual/mixed viruses at baseline [International
Workshop on HIV and Hepatitis Virus Drug Resistance and
Curative Strategies, abstract 76].
These results suggest that the characterization of HIV spe-
cies with distinct values of FPR may provide additional infor-
mation regarding tropism characteristics of the viral
populations present in plasma, but also regarding the biologi-
cal characteristics of the virus (replication capacity, cyto-
pathic effect, etc.).
Therefore, the aim of this study is to evaluate whether a
genotypic analysis of co-receptor tropism correlates with
HIV-related markers such as CD4 cell count and plasma
HIV-RNA in ART-naive and ART-experienced patients.
Materials and Methods
Patients
The study included 1573 HIV-1-infected patients followed in
different hospitals in central Italy. In order to reduce the
data contamination (and the potential misinterpretation from
a clinical perspective) induced by the natural variability of
HIV subtypes, only subtype-B HIV-1 infected patients were
analysed. For this reason, 352 patients carrying the non-B
subtype were excluded from the study, which focused on
1221 (all subtype B) infected patients.
The HIV-1 gp120 V3 region was available for all 1221
patients. The majority of V3 sequences were performed for
research purposes (about 97%), while the remaining 3% were
screened before initiating treatment with maraviroc. At the
time of genotypic test, all patients were naive to maraviroc.
In particular, 532 patients were ART naive, while 689 were
ART-experienced patients (about 30% in therapy-interrup-
tion for any reason, all others in therapeutic failure).
V3 sequencing
HIV-1 gp120 V3 loop sequencing was performed on plasma
samples by using a well-validated research-use protocol,
based on commercially available RNA-extraction (QIAamp
RNA Viral Mini kit, Qiagen, Valencia, CA, USA), reverse-
transcription and amplification (SuperScript One-Step RT-
PCR for Long Templates; Invitrogen) and genotyping (BigDye
terminator v.3.1 cycle sequencing kit; Applied Biosystems,
Foster City, CA, USA) kits, as previously described [17].
Amplified Gp120 V3 products were full-length sequenced in
sense and antisense orientations by an automated sequencer
(ABI 3130) by using four different overlapping sequence-spe-
cific primers to ensure the coverage of the V3 sequence by
at least two sequence segments [17].
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Genotypic subtyping
HIV-1 subtype was determined by using phylogenetic analysis
on HIV-1 V3 sequences. Briefly, the sequences were aligned
with HIV-1 reference sequences of all subtypes (http://
www.hiv.lanl.gov). The alignment was edited using the BioEd-
it program version 7.0.5.3. Phylogenetic trees were esti-
mated using the PAUP* package [18]. The transversion
model (GTR + I + G) of nucleotide substitution was chosen
using Modeltest v.3.7 implemented in PAUP* [19], and then
manually modified to optimize parameter settings for each
dataset. Maximum likelihood trees were inferred from
selected models using tree bisection-reconnection (TBR)
branch swapping.
Genotypic prediction of viral tropism
HIV-1 co-receptor usage was determined from the V3 nucle-
otide sequence by using the G2P algorithm available at the
following website: http://coreceptor.bioinf.mpi-inf.mpg.de/
[13]. G2P was set at FPR of 10%, thus patients with FPR
£10% were considered infected with X4-tropic viruses
according to guidelines [11]. Moreover, based on the recent
observations on the enrichment in the X4 viral population
and the loss of maraviroc activity related to FPR £2% [18th
Conference on Retroviruses and Opportunistic Infections,
abstract 667; 47th Meeting of Infectious Diseases Society of
America, abstract 297], the X4-infected patients were
explored more deeply by further categorization into two dif-
ferent subgroups: patients with FPR £2% and patients with
FPR ranging from 2% to 10%.
Statistical analysis
All analyses were performed using the statistical software
package SPSS (version 17.0) for Windows (SPSS Inc., Chi-
cago, IL, USA). ART-naive and ART-experienced patients
were analysed as two separate populations.
Genotypic prediction of viral tropism
Differences in the prevalence of the two ‘X4-tropic’ subgroups
(FPR£2% and FPR 2–10%) among ART-naive patients and
ART-experienced patients were tested for by Fisher’s exact
test; p values <0.05 were considered statistically significant.
Evaluation of relationship between genotypic tropism prediction
and immuno-virological parameters. The prevalence of X4-
infected patients was calculated and compared according to
several ranges of CD4 cell count (£200, 200–350, 350–500,
>500 cells/mm3) and HIV-RNA (<2, 2–3, 3–4, 4–5, 5–5.69,
>5.69 log10 copies/ml). Differences in the proportion of X4-
or R5-infected patients within different ranges of CD4 cell
count and viral load were evaluated by both chi-square test
for trend and Fisher exact test.
Particular attention was paid to patients with advanced
HIV-1 infection (having CD4 cell count £200 cells/mm3). The
risk of having advanced HIV infection was evaluated among
patients having different FPR ranges: (i) X4 (FPR £ 10%) vs.
R5 (FPR > 10%); (ii) X4 (FPR 2–10%) vs. R5 (FPR > 10%);
(iii) X4 (FPR £ 2%) vs. X4 (FPR 2–10%); (iv) X4 (FPR £ 2%)
vs. X4 + R5 (FPR > 2%). This risk was calculated as odds
ratio (OR) with 95% confidence (CI) interval by 2 · 2 con-
tingency tables.
In order to evaluate the role of genotypic tropism in dis-
ease progression, multivariable logistic regression analyses
were also performed both in ART-naive and ART-experi-
enced patients by adjusting for the following variables: plasma
HIV-RNA at the time of V3 genotyping, age, sex and risk
transmission factor. For ART-experienced patients the fol-
lowing variables were also considered: number of ART regi-
mens, years of ART treatment at the V3 genotyping and
therapy status (treatment vs. interrupted). The analyses were
performed in a subset of ART-naive patients (n = 332) and
ART-experienced (n = 288) patients, for whom all the con-
founding variables were available. Analysis of the missing data
was performed to evaluate if the subsets were representa-
tive of the full set population; p values <0.05 were consid-
ered statistically significant.
V3 mutation prevalence and association with different FPR ranges. In
order to assess the association of V3 mutations with geno-
typic-determined tropism, the prevalence of mutations was
calculated and compared in different FPR ranges (£2%, 2–
10%, >10%). Statistically significant differences in the muta-
tion frequency between the different groups were calculated
by using Fisher’s exact test. The Benjamini–Hochberg
method was used to correct for multiple testing at a false
discovery rate of 0.05 [20]. All mutations that were found at
the 35 V3 positions with an overall prevalence ‡1% were
evaluated.
Results
Patients’ characteristics
Patients’ characteristics are summarized in Table 1. As
expected, the median plasma HIV-RNA and CD4 cell count
were higher in ART-naive patients than in ART-experienced
patients (plasma HIV RNA, 4.7 (4.2–5.3) vs. 4.3 (3.5–4.9)
log10 copies/ml, p <0.001, by Mann Whitney U-test; CD4-cell
count, 331 (201–448) vs. 282 (138–422) cells/mm3,
p <0.001).
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Prevalence of patients infected with X4-tropic viruses
Overall, 314 out of 1221 (25.7%) patients showed X4-using
viruses at genotypic tropism testing (FPR set at 10%). No sig-
nificant differences in the prevalence of X4-using viruses was
observed between ART-naive and ART-experienced patients
(25.0% vs. 26.2%, p 0.644, Fisher’s exact test) (Fig. 1). How-
ever, when the analysis was performed using 2% as FPR cut-
off, a lower proportion of ART-naive patients had FPR £2%
in comparison with ART-experienced patients (4.9% vs.
12.6%, respectively, p <0.001) (Fig. 1). Within ART-experi-
enced patients, a lower prevalence of X4 tropic virus was
found among patients in treatment-interruption in compari-
son with those who were treated (FPR set at 10%, 20.4% vs.
28.4, p 0.040; FPR set at 2%, 7.5 vs. 14.3, p 0.014).
Evaluation of relationship between genotypic tropism
prediction and immuno-virological parameters
According to different CD4 cell count ranges (£200, 200–
350, 350–500, >500 cells/mm3), significant differences in the
proportion of X4-infected patients with FPR £2% were
observed, both in ART-naive (11.2% vs. 4.7%, 2.7% and
0.8%, respectively, p <0.001 by chi-square for trend) and
ART-experienced patients (19.2% vs. 8.6%, 8.9%, and 10.2%
respectively, p 0.003) (Fig. 2a,b). It is noteworthy that,
within ART-experienced patients, a different trend in the
proportion of tropism groups was observed for CD4 cell
count range 200–350 mm3 (Fig. 2b). This atypical trend can
be explained by the different tropism prevalence found
between treated patients (FPR (%) £2, 9.9%; FPR 2–10,
14%; FPR > 10, 76%) and those who interrupted therapy
(FPR (%) £ 2, 5.7%; FPR 2–10, 3.8%; FPR > 10, 90.6%)
(p 0.063).
However, we did not observe differences in tropism prev-
alence in the stratum of patients with CD4 £200 cells/mm3;
of interest is that we observed no significant differences
when the same analysis was performed for patients with FPR
2–10% along different CD4 cell count ranges. Therefore, the
difference in genotypic tropism found in patients with CD4
£200/mm3, was mostly accounted for by FPR rank £2%.
When we considered different FPR ranges according to
HIV-RNA ranges, no significant differences in the proportion
of patients infected by X4-tropic viruses were observed,
both in ART-naive and ART-experienced patients (data not
shown). Therefore, FPR £2% significantly correlates with
immunological status, but not with viral load.
Risk of having advanced HIV-1 infection according to X4-
tropism
In ART-naive patients, by setting FPR at 2%, the risk of hav-
ing advanced HIV-1 infection (CD4 £200/mm3) was signifi-
cantly higher in patients with FPR £2% vs. FPR > 2% (OR (CI
95%), 4.2 (1.8–9.2), p 0.0006), while this risk was not signifi-
cant when FPR was set at 10% (Fig. 3).
The role of X4 tropism as a significant independent pre-
dictor of advanced HIV-1 infection was confirmed, with FPR
set at 2%, also by multivariable logistic regression (OR (95%
CI), 3.4 (1.0–11.643), p 0.047).
In ART-experienced patients, FPR set at 2% was also asso-
ciated with a significantly higher risk of having advanced HIV-
1 infection compared with patients infected by viruses with
FPR >2% (OR (95% CI), 2.3 (1.4–3.6), p 0.0003). In contrast
to the ART-naive population, this finding was significant also
for FPR set at 10% (Fig. 3). By multivariable logistic regres-
sion analysis (after adjusting for all the confounders indicated
in the Materials and Methods section, including therapy inter-
ruption), tropism was confirmed as an independent predictor
of advanced HIV-1 infection by setting FPR at both 2% (OR
(CI 95%), 6.0 (2.4–15.0), p <0.0001) and 10% (3.0 (1.6–2.7),
p 0.001).
TABLE 1. Patients’ characteristics
Characteristics
ART-naive
patients
(n = 532)
ART-experienced
patients
(n = 689)
Age (years), mediana 38 45
Gender, male % 87.1 71.6
Risk transmission factor, %b
Heterosexual 24.4 28.8
Homosexual 52.4 20.4
Sexual 12.2 8.5
IDU 10.4 39.2
Other (iatrogenic or
perinatal transmission)
0.6 3.1
CDC stage, %c A (56.3) A (19.0)
B (31.1) B (31.6)
C (12.6) C (49.4)
Viraemia (log10 copies/ml),
median (IQR)d
4.7 (4.2–5.3) 4.3 (3.5–4.9)
CD4 cell count, median (IQR)
(cells/mm3)d
331 (201–448) 282 (138–422)
Pts with CD4 cell count £200
cells/mm3, %d
23.5 33.9
Therapy protocol at
V3 sequencing, n
– Treated: 425
Treatment
interruption: 186
Unknown: 78
Previous treatment, median (IQR)e
Number of regimens 4 (2–7)
Number of ARV drugs 8 (4–10)
Experienced drug class, %e
NRTI 100
NNRTI 67.8
PI 85.2
FI 7.0
INI 8.8
Years of ART treatmente, median (IQR) - 10 (5–14)
ART, antiretroviral therapy; ARV, antiretroviral; FI, fusion inhibitors; IDU, injec-
tion drug user; INI, integrase inhibitors; NRTI, nucleoside/nucleotide reverse
transcriptase inhibitors; NNRTI, non-NRTI; pts, patients; PI, protease inhibitors.
aAge was available for 497 ART-naive patients and 580 ART-experienced
patients.
bRisk transmission factors were available for 393 ART-naive patients and 520
ART-experienced patients.
cCDC stage at the moment of V3 sequencing was available for 206 ART-naive
patients and 256 ART-experienced patients.
dAvailable values at the moment of V3 sequencing.
eComplete therapeutic history was available for 406 ART-experienced patients.
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All these findings reinforce the relationship between very
low FPR and advanced HIV-1 infection, though with different
evidence (and potentially mechanisms) in ART-naive and
ART-experienced patients.
V3 mutations associated with different FPR ranges
Table 2 shows the prevalence of mutations according to FPR
ranges (£2%, 2–10%, >10%). Among 85 V3 mutations found
with prevalence ‡1% in our cohort of ART-naive patients,
(4.9%)
ART-experienced patients 
FPR 2-10
FPR 2-10
(13.6%)
R5
(75.0%)
(20.1%)
FPR  2 
X4
(25.0%)
R5
(73.8%)
FPR 2
(12.6%)
X4 
(26.2%)
(a) (b)ART-naive patients 
FIG. 1. Proportion of patients infected with X4- and R5-tropic viruses. (Panel a) Antiretroviral therapy (ART)-naive patients. (Panel b) ART-
experienced patients. The proportions of R5-infected (FPR>10%, in white) and X4-infected (FPR£10%, grey lines) patients are indicated in the
pie plots. Exploded bars represent the stratification of X4-infected patients according to 2% FPR-X4 ranges (FPR 2–10%, in dark grey; FPR£2%,
in black).
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ART-experienced patients
Tropism FPR (%) P value
R5 >10 0.008
X4 2–10 0.235
X4 ≤2 0.003
ART-naive patients
Tropism FPR (%) P value
R5 >10 0.023
X4 2–10 0.398
X4 ≤2 0.001
≤200 200–350 350–500 >500
N = 234 N = 174 N = 124 N = 157
≤200 200–350 350–500 >500
FIG. 2. Proportion of X4- and R5-infected patients according to different CD4 cell count ranges. (Panel a) Proportion of antiretroviral therapy
(ART)-naive patients stratified for different CD4 cell count ranges. (Panel b) Proportion of ART-experienced patients stratified for different CD4
cell count ranges. Bar plots indicate the proportion of X4-infected patients with FPR £2% (in black) or FPR 2–10% (in grey), and the proportion
of R5-infected patients (in white), all of them stratified for different CD4 cell count ranges. Tables inserted in the figure indicate the p values
obtained by chi-square test for trend used to calculate potential differences in the proportion of patients for the following groups: (i) patients
with FPR £2% vs. those with FPR >2%; (ii) patients with FPR 2–10% vs. those with FPR >10%, (iii) patients with FPR £2% vs. those with FPR
>2%. In bold are reported p values considered statistically significant (<0.05).
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only five were significantly associated with FPR £2%. Four of
them (S11R, Y21V, G24K, G24R) also remained strongly
associated with FPR £2% after multiple comparisons. It is
noteworthy that the prevalence of S11R mutation was
strongly associated with FPR £2% (p <0.001). Similarly, the
mutations Y21V, G24K and G24R were highly present in
patients with FPR £2% and nearly absent in patients with
FPR >2% (p £0.001).
Among 91 V3 mutations found with prevalence ‡1% in
ART-experienced patients, only eight mutations were signifi-
cantly associated with FPR £2%. Six of them (N7K, N7Y,
S11R, H13Y, H13S and R18S) remained strongly associated
with FPR £2% after multiple comparisons. In particular,
mutations N7K and H13Y were present in patients with FPR
£2% and nearly absent in other patients (p £0.002). As in
naive patients, it is noteworthy that the prevalence of the
S11R mutation was strongly associated with FPR £2% and it
was completely absent in patients with FPR >10%.
Discussion
The present study, which was carried out with a large
cohort of ART-naive and ART-experienced patients, shows
that a genotypic analysis of co-receptor tropism correlates
with CD4 cell count (but not with viral load). The lowest
X4 FPR was associated with greater CD4 depletion in HIV-1
infected patients. So far, few studies (with a relatively small
number of patients) have highlighted a similar type of associ-
ation [6,16; 3rd Italian Conference on AIDS and Retrovirus-
es, abstract SC16; International Workshop on HIV and
Hepatitis Virus Drug Resistance and Curative Strategies,
abstract 89].
In the present study, about one-quarter of patients (either
ART naive or ART experienced) were carrying predominant
X4-tropic viruses (using the classical 10% FPR cut-off). A
higher proportion of X4-tropic virus was also found in
patients with a relatively high CD4 cell count (as shown in
Fig. 2). This result was surprising because the appearance of
the X4 virus is commonly considered as typical of advanced
stages of the disease, thus suggesting that the pathogenetic
mechanisms of progression of HIV infection are more com-
plex than thought up to now. So far, co-receptor tropism
testing remains mandatory in all patients planning to start
therapy with CCR5 antagonists, independently of their CD4
number and stage of the disease.
Genotypic tropism analysis was also performed using 2% as
FPR cut-off, a category that better defines pure X4 virus,
insensitive to CCR5 antagonists, and it was compared with
the classical FPR set at 10% [47th meeting of Infectious Dis-
eases Society of America, abstract 297; International Work-
shop on HIV and Hepatitis Virus Drug Resistance and
Curative Strategies, abstract 76]. A lower proportion of ART-
naive patients carrying predominant viruses with FPR £2%
compared with ART-experienced patients (4.9% vs. 12.6%,
respectively) was found. Viruses with FPR £2% were nearly
absent (0.8%) in ART-naive patients with CD4 > 500 cells/
mm3, compared with almost 20% prevalence in the same
4.2
4.5
0.9
1.3
0.1 1.0 10.0
P = 0.404 
P = 0.288 
2.3
1.7
1.4
1.9
0.1 1.0 10.0
P = 0.075 
P = 0.074 
P = 0.0003 
P = 0.0002 
FPR 
Cut-offs (%) 
ART-naive patients 
Odd ratio (95% C.I.) 
ART-experienced patients 
Odd ratio (95% C.I.) 
P = 0.0006 
P = 0.0012 
FPR2 ≤ vs. FPR >2
FPR ≤ 2 vs. FPR 2-10
FPR 2-10 vs. FPR >10
FPR ≤ 10 vs. FPR >10
FIG. 3. Risk of having CD4 cell count £200 cells/mm3 by false-positive rate ranges in antiretroviral therapy (ART)-experienced and ART-naive
patients. Forest plots represent the odds ratios (with 95% confidence interval) of having CD4 cell count £200 cells mm3 calculated comparing
several categories of patients having different FPR ranges. On the left panel are ART-naive patients; on the right panel are ART-experienced
patients; p values were obtained by Fisher’s exact test and were considered statistically significant at a threshold of 0.05.
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category of patients, if the FPR threshold is set at 10% (instead
of 2%). This discrepancy suggests that today the use of FPR
needs refinement to better and more uniformly identify those
patients that, carrying a predominant pure X4 virus, have very
low/no chances of taking advantage of CCR5 antagonists.
The setting of FPR at £2% shows a tight relationship
between this parameter and CD4 £200 cells/mm3, which
was not found in ART-naive patients with FPR set at 10%,
that, in ART-naive patients, could not be found with FPR set
at 10%. This suggests that viral strains with FPR £2% might
be associated with a more cytopathic effect. A recent study,
performed in our laboratory on 54 HIV-1 primary isolates,
supports this hypothesis [21]. Indeed, viral isolates with FPRs
<2% were associated with an extensive prevalence of
X4-using viruses, with a syncytium-inducing phenotype, a
marked cytopathic effect and loss of activity of CCR5-antag-
onist maraviroc in vitro. On the contrary, clinical isolates with
FPR ranging from 2% to 10% (as well as nearly all isolates
with FPR >10%) were unable to induce syncytium formation
and most of them were still sensitive to maraviroc [21]. Of
interest, is that our data do not show any significant relation-
ship between tropism and viraemia. In the same in vitro
experiments reported above [21], viral production was simi-
lar in CD4-T cells infected by clinical isolates with FPR<2%
TABLE 2. Prevalence of V3 mutations associated with different FPR ranges in ART-naive and ART-experienced patients
Prevalence according with FPR ranges N (%)
FPR ranges £2% 2–10%
p Valuea
>10%
p Valueb
Overall
ART-naive patients N = 25 N = 108 N = 399 N = 532
Position Mutations
2 T2M 0 (0.0) 5 (4.6) 0.583 1 (0.3) 0.002 6 (1.1)
9 R9S 3 (12.0) 8 (7.4) 0.432 6 (1.5) 0.003 17 (3.2)
11 S11R 23 (92.0) 7 (6.5) <0.001 0 (0.0) <0.001 30 (5.6)
12 I12L 0 (0.0) 6 (5.6) 0.594 0 (0.0) <0.001 6 (1.1)
13 H13G 1 (4.0) 6 (5.6) 1.000 2 (0.5) 0.002 9 (1.7)
14 I14L 2 (8.0) 25 (23.1) 0.105 24 (6.0) <0.001 51 (9.6)
14 I14V 1 (4.0) 5 (4.6) 1.000 2 (0.5) 0.006 8 (1.5)
16 P16G 1 (4.0) 4 (3.7) 1.000 1 (0.3) 0.008 6 (1.1)
19 A19V 8 (32.0) 14 (13.0) 0.034 17 (4.3) 0.002 39 (7.3)
20 F20V 1 (4.0) 6 (5.6) 1.000 1 (0.3) <0.001 8 (1.5)
20 F20Y 4 (16.0) 9 (8.3) 0.265 6 (1.5) 0.001 19 (3.6)
21 Y21V 5 (20.0) 0 (0.0) <0.001 8 (2.0) 0.212 13 (2.4)
21 Y21H 1 (4.0) 9 (8.3) 0.687 2 (0.5) <0.001 12 (2.3)
22 T22A 12 (48.0) 58 (53.7) 0.661 286 (71.7) 0.001 356 (66.9)
23 T23A 2 (8.0) 8 (7.4) 1.000 8 (2.0) 0.009 18 (3.4)
24 G24R 6 (24.0) 2 (1.9) 0.001 1 (0.3) 0.116 9 (1.7)
24 G24K 4 (16.0) 0 (0.0) 0.001 2 (0.5) 1.000 6 (1.1)
24 G24E 6 (24.0) 18 (16.7) 0.395 10 (2.5) <0.001 34 (6.4)
25 E25K 3 (12.0) 16 (14.8) 1.000 11 (2.8) <0.001 30 (5.6)
25 E25R 3 (12.0) 11 (10.2) 0.727 8 (2.0) <0.001 22 (4.1)
32 Q32R 2 (8.0) 13 (12.0) 0.736 13 (3.3) 0.001 28 (5.3)
ART-experienced patients N = 85 N = 96 p Valuea N = 508 p Valueb N = 689
7 N7K 8 (9.4) 0 (0.0) 0.002 0 (0.0) 1.000 8 (1.2)
7 N7Y 12 (14.1) 2 (2.1) 0.004 0 (0.0) 0.025 14 (2.0)
9 R9S 7 (8.2) 8 (8.3) 1.000 3 (0.6) <0.001 18 (2.6)
11 S11R 54 (63.5) 12 (12.5) <0.001 0 (0.0) <0.001 66 (9.6)
12 I12V 8 (9.4) 12 (12.5) 0.636 19 (3.7) 0.001 39 (5.7)
13 H13Y 13 (15.3) 0 (0.0) <0.001 2 (0.4) 1.000 15 (2.2)
13 H13R 9 (10.6) 9 (9.4) 0.808 13 (2.6) <0.001 31 (4.5)
13 H13S 20 (23.5) 7 (7.3) 0.003 30 (5.9) 0.641 57 (8.3)
14 I14V 8 (9.4) 8 (8.3) 0.800 7 (1.4) <0.001 23 (3.3)
14 I14L 14 (16.5) 14 (14.6) 0.837 32 (6.3) 0.010 60 (8.7)
15 G15A 0 (0.0) 0 (0.0) 1.000 29 (5.7) 0.008 29 (4.2)
18 R18S 1 (1.2) 18 (18.8) <0.001 49 (9.6) 0.013 68 (9.9)
19 A19V 25 (29.4) 11 (11.5) 0.003 18 (3.5) 0.003 54 (7.8)
20 F20I 3 (3.5) 9 (9.4) 0.142 15 (3.0) 0.007 27 (3.9)
22 T22A 37 (43.5) 53 (55.2) 0.137 363 (71.5) 0.003 453 (65.7)
23 T23A 6 (7.1) 15 (15.6) 0.103 22 (4.3) <0.001 43 (6.2)
24 G24D 1 (1.2) 9 (9.4) 0.020 4 (0.8) <0.001 14 (2.0)
24 G24R 10 (11.8) 6 (6.3) 0.294 4 (0.8) 0.002 20 (2.9)
24 G24E 15 (17.6) 20 (20.8) 0.707 11 (2.2) <0.001 46 (6.7)
25 E25T 2 (2.4) 5 (5.2) 0.450 1 (0.2) <0.001 8 (1.2)
25 E25R 17 (20.0) 16 (16.7) 0.570 7 (1.4) <0.001 40 (5.8)
25 E25K 18 (21.2) 22 (22.9) 0.858 13 (2.6) <0.001 53 (7.7)
25 E25D 12 (14.1) 17 (17.7) 0.548 243 (47.8) <0.001 272 (39.5)
32 Q32R 16 (18.8) 14 (14.6) 0.549 18 (3.5) <0.001 48 (7.0)
ART, antiretroviral therapy; FPR, false positive range.
p Values significant at a false discovery rate of 0.05 following correction for multiple comparison are shown in boldface.
ap Value for comparison between FPR £2% vs. FPR2–10% groups.
bp Value for comparison between FPR 2–10% vs. FPR >10% groups.
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compared with the others. All together, our data support
the hypothesis that FPR values that are particularly low are
related to the cytopathic effect of the virus, and, in turn, to
loss of CD4 cell count, but not viral load.
Genotypic analysis confirmed the difference between
viruses with FPR £2% compared with 2–10%. Indeed,
X4-related mutation S11R and some other X4-related muta-
tions [13,22] were found in ART-naive patients (Y21V, G24K
and G24R) or ART-treated patients (Y7K, H13Y) as strongly
associated with FPR £2% (but not with FPR 2–10%), thus
suggesting their contribution to the characterization of
‘pure-X4-tropic viruses’.
All these data together show that FPR ranges between 2%
and 10% represent a grey area, not necessarily representing
pure X4-tropic viruses, and not necessarily associated with low
CD4 cell count (and therefore with advanced stages of disease).
This study may have some limitations. First of all, genotypic
tropism was determined by the analysis of only the V3
sequences. In this regard, even if a single specific amino acid
change in the V3 loop can switch viral co-receptor usage [23–
25], it is known that other residues outside of the V3 loop
within gp120 and gp41 could be relevant for viral co-receptor
usage [26–28]. Our cohort includes only subtype B viruses.
Therefore, the results obtained in this study cannot be applied
to other cohorts containing non-B viruses. Another potential
limitation is that this study is cross-sectional; therefore it is
not designed to define whether X4 viruses with FPR £2% are a
cause or consequence of having low CD4 cell count. Regarding
this, recent studies suggest that the appearance of the X4-tro-
pic virus is more a consequence of depletion of the immune
system than the cause [29]. Finally, it would be interesting to
evaluate the relationship between the duration of HIV-1 infec-
tion and the genotypic tropism. However, analysing patients
from clinical practice, it was not possible to evaluate this issue,
because the diagnosis is frequently made after a time of infec-
tion that cannot be quantified.
In conclusion, very low FPR defines patients carrying a
viral population significantly associated with low CD4 rank,
and thus with a greater risk of advanced disease. All these
findings together suggest that low FPR (£2%) may better
identify those patients whose virus is insensitive to CCR5-
inhibitors, and can be a surrogate marker of a compromised
immune system.
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Appendix
Members of the OSCAR (Optimizing the Susceptibility to
CCR5 Antagonists Response) Study group
The complete list of centres and members participating in
the OSCAR programme is as follows. ‘San Raffaele’ Hospital
(Milan): Adriano Lazzarin, Massimo Clementi, Silvia Nozza,
Filippo Canducci, Enzo Boeri. ‘L. Sacco’ Hospital (Milan): Giu-
liano Rizzardini, Massimo Galli, Valeria Micheli. ‘S. Paolo’
Hospital (Milan): Antonella D’Arminio Monforte. Busto Ars-
izio Hospital (Busto Arsizio [MI]): Tiziana Quirino. ‘S. Ger-
ardo’ Hospital, (Monza [MI]): Andrea Gori. Ospedali Riuniti
(Bergamo): Franco Maggiolo, Anna Paola Callegaro. IRCCS
Policlinico S. Matteo (Pavia): Renato Maserati, Fausto Baldan-
ti, Stefania Paolucci. University of Turin (Turin): Giovanni Di
Perri, Valeria Ghisetti, Tiziano Allice. Policlinico ‘S. Orsola-
Malpighi’ (Bologna): Marco Borderi, Maria Carla Re, Isabella
Bon. ‘San Martino’ Hosptial (Genova): Claudio Viscoli, Anto-
nio Di Biagio, Bianca Bruzzone. Policlinico of Modena (Mode-
na): Cristina Mussini, William Gennari, Monica Pecorari.
Marche Politechnic University Medical School (Ancona):
Andrea Giacometti, Alessia Monachetti, Patrizia Bagnarelli.
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‘S.M. Annunziata’ Hospital (Firenze): Francesco Mazzotta,
Massimo Di Pietro. ‘Careggi’ Hospital (Firenze): Francesco
Leoncini, Gaetana Sterrantino. University of Siena (Siena):
Maurizio Zazzi. Policlinico’Tor Vergata’ (Rome): Massimo An-
dreoni. I.N.M.I. ‘L. Spallanzani’ (Rome): Andrea Antinori, Car-
lo Federico Perno, Roberta D’Arrigo. University of Rome ‘La
Sapienza’ (Rome): Vincenzo Vullo, Guido Antonelli, Ombret-
ta Turriziani. Catholic University ‘Sacro Cuore’ (Rome):
Roberto Cauda, Andrea De Luca, Giovanni Fadda, Maria
Rosaria Santangelo. University of Foggia and Bari: Gioacchino
Angarano, Laura Monno, Annalisa Saracino, Grazia Punzi.
Members of SENDIH (Studio Epidemiologico Nuove
Diagnosi Infezione da HIV) Study Group
The complete list of centres and members participating in
the SENDIH programme is as follows. R. Balzano, M. R. Ca-
pobianchi, R. D’Arrigo, G. De Carli, P. Elia, V. Galati, E. Gir-
ardi, C. Gori, S. Grisetti, A. Navarra, E. Nicastri, N. Orchi,
C. F. Perno, S. Pittalis, V. Puro, A. Sampaolesi, P. Scognami-
glio, G. Nurra, M. Selleri, M. Zaccarelli, M. S. Zaniratti
(National Institute for Infective Diseases, L. Spallanzani,
Rome); A. Di Carlo, M. Giuliani (Division of Dermatological
Infectious Diseases, STI/HIV Unit, San Gallicano Institute,
Rome); A. De Filippis (U.O. AIDS S. Eugenio, ASL RMC,
Rome); R. Brancatella, T. Maggi (U.O. AIDS ASL RMB S. Per-
tini Hospital, Rome); P. Gattari, L. Spizzichino (UO AIDS
ASL RME, Rome); S. Schito (UO AIDS ASL RMD GB Grassi
Hospital, Rome); L. Sarmati, G. Battagin (Clinical Infectious
Diseases Unit, Tor Vergata University, Roma), L. Tacconi
(CRAIDS Hospital, Latina); I. Gallo, E. Anzalone (CRAIDS
Hospital, Frosinone); A. Pitorri (CRAIDS Hospital, Rieti); A.
Caterini, S. Aviani Barbacci (CRAIDS Hospital, Viterbo).
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